Impact of Extracorporeal Life Support on Cardiogenic Shock Patients

Extracorporeal Life Support in Infarct-Related Cardiogenic Shock

A multicenter trial examined the use of extracorporeal life support (ECLS) in patients with acute myocardial infarction complicated by cardiogenic shock. The study found that ECLS therapy did not significantly reduce the risk of death at 30 days compared to those who received medical therapy alone. However, ECLS was associated with higher rates of bleeding and peripheral vascular complications.


Similar Posts